2021 – The healthcare changes here to stay2020 was the year that changed everything, and as the new year begins many are wondering what awaits Share X2021 – The healthcare changes here to stayhttps://pharmaphorum.com/views-analysis-digital/2021-healthcare-change/
Angelini and Arvelle create neurology player with $960m mergerThere’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Share XAngelini and Arvelle create neurology player with $960m mergerhttps://pharmaphorum.com/news/angelini-and-arvelle-create-neurology-player-with-960m-merger/
AI-designed serotonin tracker could help develop neurology drugsA serotonin sensor designed using Artificial Intelligence (AI) could help scientists study sleep and mental health and potentially Share XAI-designed serotonin tracker could help develop neurology drugshttps://pharmaphorum.com/news/us-scientists-use-ai-to-design/
Lundbeck tops Q3 expectations following strong sales of mental health drugsDenmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of Share XLundbeck tops Q3 expectations following strong sales of mental health drugshttps://pharmaphorum.com/news/lundbeck-tops-q3-expectations-following-strong-sales-of-mental-health-drugs/
A new approach to mental health – the Health Heroes podcastThe third episode of Kantar’s Health Heroes podcast looks at the effects of increased anxiety on patients’ attitudes Share XA new approach to mental health – the Health Heroes podcasthttps://pharmaphorum.com/podcast/mental-health-covid-19-telehealth/
Retired NFL Linebacker Overcomes ADHD, Invests in Mental Health Platform DoneMental health platform Done makes its debut Share XRetired NFL Linebacker Overcomes ADHD, Invests in Mental Health Platform Donehttps://pharmaphorum.com/partner-content/retired-nfl-linebacker-overcomes-adhd-invests-in-mental-health-platform-done/
MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOCompass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy Share XMindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOhttps://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/
BioXcel’s phase 3 schizophrenia film has blockbuster potential, say analystsA sublingual film for acute agitation in schizophrenia and bipolar disorder from BioXcel has blockbuster potential that could Share XBioXcel’s phase 3 schizophrenia film has blockbuster potential, say analystshttps://pharmaphorum.com/news/bioxcel/
Compass plans $100m IPO to fund magic mushroom depression drugUK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its Share XCompass plans $100m IPO to fund magic mushroom depression drughttps://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/